Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 01, 2014, 12:30:21 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 640684
  • Total Topics: 48666
  • Online Today: 205
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: HCQ-01 - Hydroxychloroquine study  (Read 1446 times)

0 Members and 1 Guest are viewing this topic.

Offline newt

  • Member
  • Posts: 3,885
  • the one and original newt
HCQ-01 - Hydroxychloroquine study
« on: September 14, 2008, 11:09:04 AM »
"Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation and viral replication in asymptomatic Human Immunodeficiency Virus (HIV)-infected patients" ie some of us folk.

A phase II, multi-centre, randomised, double-blind, placebo-controlled clinical trial

Details of this study were requested in this thread:
http://forums.poz.com/index.php?topic=23019.0

The ISRCTN register entry for this trial is: ISRCTN30019040

This study aims to determine whether hydroxychloroquine decreases immune activation in HIV, measured by least a 25% reduction in CD8 T-cell activation after 48 weeks of treatment. The study also intends to examine the effects of hydroxychloroquine on viral load and CD4 T-cell count at week 48, and to assess safety of hydroxychloroquine in this patient population.

The primary outcome measure is change in CD8 T-cell activation at week 48 compared to baseline in the two study groups (as shown by a percentage of the cells expressing CD38+ and HLA-DR+).

Secondary efficacy outcome measures, considered as change from baseline to week 48:

1. CD4 T-cell activation (as shown by the percentage of the cells expressing CD38+ and HLA-DR+)
2. Absolute CD4 T-cell count
3. IL-6 concentration
4. HIV viral load (expressed in log^10 copies/ml)

plus a bunch on safety and tolerability.

Community representation arranged via the UK-CAB.

This is a Medical Research Council Clinical Trials Unit study and will recruit across the UK.

- matt



"The object is to be a well patient, not a good patient"

Offline leit

  • Member
  • Posts: 236
Re: HCQ-01 - Hydroxychloroquine study
« Reply #1 on: September 14, 2008, 07:47:19 PM »

Thank you very much, "newt" and... let's hope!

Only a doubt: hydroxychloroquine "inhibits the posttranslational modification of glycoprotein 120 (gp 120) in T cells and monocytes", so it itself inhibits HIV. Don't you think this could be a confounding factor?

Another question, please: the above linked abstract talks about newly and chronically infected T and monocytic cells. Are those "newly" and "chronically" synonymous with something else?

Thanks again!

« Last Edit: September 14, 2008, 07:48:52 PM by leit »

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.